Do we need antivirals for genital herpes simplex virus and human papillomavirus infection?

International Journal of Antimicrobial Agents

Volumn 12, Issue 1, 1999, Pages 1-3

  Gross, G ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; BETA INTERFERON; CIDOFOVIR; FAMCICLOVIR; IMIQUIMOD; PENCICLOVIR; VALACICLOVIR;

ARTICLE; CONDYLOMA; DRUG EFFICACY; DRUG SAFETY; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RECURRENCE RISK; SEXUALLY TRANSMITTED DISEASE; TOPICAL DRUG ADMINISTRATION; WART VIRUS;

ADOLESCENT; ADULT; ANIMALS; ANTIVIRAL AGENTS; CHILD; FEMALE; HERPES GENITALIS; HUMANS; MICE; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; TREATMENT OUTCOME; TUMOR VIRUS INFECTIONS;

EID: 0032973006     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(99)00004-7     Document Type: Article

References (39)

1. American Social Health Association. Awareness of Sexually Transmitted Diseases: An International Study, 1995.
2. Genital herpes infections - United States 1966-79. MMWR. 31:1982;137-139.
3. Sexually Transmitted Diseases, England 1995: new cases seen at NHS genito-urinary medicine clinics. 1996;1-15 HM Stationery Office, London.
4. Marchant Roe A. Genital herpes: recognizing and addressing patients' needs. Herpes J. 4:1997;36-41.
5. Mindel A. Genital herpes - how much of a public-health problem? Lancet. 351(Suppl. III):1998;16-18.
6. Fleming D.T., McQuillan G.M., Johnson R.A. et al. Herpes simplex in the United States 1976-1994. New Engl. J. Med. 337:1997;1105-1111.
7. Kassler W.D., Zenilman J.M., Erickson B. et al. Seroconversion in patients attending sexually transmitted disease clinics. AIDS. 8:1994;351-355.
8. Holmberg S.D., Stewart J.A., Gerber A.R. et al. Prior herpes simplex virus type 2 infections as a risk factor for HIV infection. J. Am. Med. Assoc. 259:1988;1048-1050.
9. Keef I.P., Lee F.K., van Griemsven G.J. et al. Herpes simplex virus type 2 and other genital ulcerative infections as a risk factor, for HIV-1 acquisition. Genitourin. Med. 66:1990;330-333.
10. Whitley R. Neonatal Herpes simplex virus infections. J. Med. Virol. Suppl. 1:1993;13-21.
11. Kaplowitz L.G., Baker D., Gelb L. et al. Prolonged continuous acyclovir treatment of normal adults with frequently recuring genital herpes simplex virus infection. J. Am. Med. Assoc. 265:1991;747-751.
12. Tilson H.H., Engle C.R., Andrews E.B. Safety of acyclovir: a summary of the first 10 years experience. J. Med. Virol. Suppl. 1:1993;67-73.
13. Mindel A, Brocklehurst P The treatment of herpes simplex virus infections. Jeffries D, De Clerq E Antiviral chemotherapy. 1995;Wiley, Chichester.
14. Spruance S.L., Tyring S.K., Degregorio B. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Arch. Intern. Med. 156:1996;1729-1735.
15. Sacks S.L., Aoki F.Y., Diaz Mitoma F. Patient-initiated, twice-daily oral famiciclovir for early recurrent genital herpes: a randomized double-blind multicenter trial. J. Am. Med. Assoc. 276:1996;44-49.
16. Thackray A.M., Field H.J. Comparison of the effect of famiciclovir and valaciclovir on pathogenesis of herpes simplex virus type 2 in a murine infection model. Antimicrob. Agents Chemother. 40:1996;846-851.
17. Ho G.Y.F., Bierman R., Beardsley L. et al. Natural history of cervicovaginal papillomavirus infection in young women. New Engl. J. Med. 338:1998;423-428.
18. Bauer H.M., Ting Y., Greer C.E. et al. Genital human papillomavirus infection in female university students as determined by a PCR-based method. J. Am. Med. Assoc. 265:1991;472-477.
19. Koutsky L.A., Holmes K.K., Critchlow C.W. et al. A cohort study of the risk of cervical intraepithelial nesplasia grade 2 or 3 in relation to papillomavirus infection. New Engl. J. Med. 327:1992;1272-1278.
20. Burk R.D., Ho G.Y.F., Beardsley L. et al. Sexual behaviour and partner characteristics are the predominant risk factors for genital human papillomavirus infection in young woman. J. Infect. Dis. 174:1996;679-689.
21. Evander M., Edlund K., Gustafsson A. et al. Human papillomavirus infection is transient in young women: a population based cohort study. J. Infect. Dis. 17:1995;1026-1030.
22. Karlsson R., Jonsson M., Edlund K. et al. Lifetime number of partners as the only independent risk factor for human papillomavirus infection: a population based study. Sex. Transm. Dis. 22:1995;119-127.
23. Fairley C.K., Chen S., Ugori A. et al. Human papillomavirus infection and its relationship to recent and distant sexual partners. Obstet. Gynecol. 84:1994;755-759.
24. Von Krogh G, Gross G. Anogenital warts. In: Orth G, Jablonska S, editors. Clinics in Dermatology, vol. 15(3). Elsevier, NY, 1997;355-368.
25. Human Papillomaviruses. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. 64:1995;IARC, Lyon.
26. Herrero R. Epidemiology of cervical cancer. Monogr. Natl. Cancer. Inst. 21:1996;1-6.
27. Krüger Kjaer S., Van den Brule A.J.C., Bock J.E. et al. Determinants for genital human papillomavirus (HPV) infection in 1000 randomly chosen young Danish women with normal PAP Swear: are there different profiles for oncogenic and nononcogenic HPV types? Cancer Epidemiol. Biomarkers Prev. 6:1997;799-805.
28. Bryan J.T., Stoler N.H., Tyring S.K. et al. High-grade dysplasia in genital warts from two patients infected with the human immumodeficiency virus. J. Med. Virol. 54:1998;69-73.
29. Palefsky J. HPV-related disease in immunosuppressed individuals. Gross G., von Krogh G. Human Papillomavirus Infections in Dermatovenereology. 1997;227-240 CRC Press, Boca Raton, FL.
30. Von Krogh G., Gross G., Barrasso R. Warts and HPV-related squamous cell tumours of the genitoanal area in adults. Gross G., von Krogh G. Human Papillomavirus Infections in Dermatovenereology. 1997;259-304 CRC Press, Boca Raton, FL.
31. Armbruster-Moraes E., Joshimoto E.M., Leao E., Zugaib M. Presence of human papillomavirus DNA in amniotic fluides of pregnant women with cervical lesions. Gynaecol. Oncol. 54:1994;152-154.
32. Obalek S., Jablonska S., Orth G. Warts and HPV-related squamous cell tumours of the genitoanal area in children. Gross G., von Krogh G. Human Papillomavirus Infections in Dermatovenereology. 1997;305-312 CRC Press, Boca Raton, FL.
33. Gross G. Therapy of human papillomavirus infection and associated epithelial tumours. Intervirology. 40:1998;368-377.
34. Edwards L., Ferenczy A., Eron L. et al. Self-administered topical 5% imiquimod cream for external anogenital warts. Arch. Dermatol. 134:1998;25-31.
35. Beutner K.R., Tyring S.K., Trofatter K.F. Jr. et al. Imiquimod, a patient-applied immune response modifier for treatment of external genital warts. Antimicrob. Agents Chemother. 42(4):1998;789-794.
36. Gross G., Rogoszinski T., Schöfer H. et al. Recombinant interferon beta gel as adjuvant in the treatment of recurrent genital warts: results of a placebo-controlled double-blind study in 120 patients. Dermatology. 196:1998;330-334.
37. Snoeck R., van Ranst M., Andrei G. et al. Treatment of anogenital papillomavirus infections with an acyclic nucleoside phosphonate analogue. New Engl. J. Med. 333:1995;943-944.
38. De Clerq E. Acyclic nucleoside phosphonates in the chemotherapy of DNA virus and retrovirus infections. Intervirology. 40:1998;295-303.
39. 2 laser swift lase and natural interferon beta gel. Acta Derm.-Venereol. 78:1998;309-310.